Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Alejandro Gutierrez, MD

  • Physician
  • Associate Professor of Pediatrics, Harvard Medical School

Appointment Phone

  • 888-733-4662 (New Pediatric Patients)
  • 617-632-3270 (Established Pediatric Patients)


  • 617-730-0934


Treatment Centers


Clinical Interests

Global health, Liposarcoma, T-cell acute lymphoblastic leukemia, Zebrafish drug screens



Board Certifications

  • Pediatric Hematology/Oncology, 2009
  • Pediatrics, 2004


  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 2007


  • Children's Hospital of Philadelphia, Pediatrics, 2004

Medical School

  • University of Pennsylvania School of Medicine, 2001


Dr. Gutierrez received an MD degree from the University of Pennsylvania School of Medicine and completed a pediatrics residency at The Children's Hospital of Philadelphia, followed by a fellowship in pediatric hematology/oncology at Boston Children's Hospital/Dana-Farber Cancer Institute. His postdoctoral research training was with Dr. A. Thomas Look at Dana-Farber Cancer Institute. Dr. Gutierrez is a Scholar of the American Society of Hematology-Harold Amos Medical Faculty Development Program and recipient of the 2010 Young Investigators Award from the American Society of Pediatric Hematology/Oncology.


The Gutierrez laboratory is focused on discovery of molecular oncogenesis and novel therapeutic targets for chemoresistant human cancers, including high-risk T-cell acute lymphoblastic leukemia and treatment-resistant sarcomas. Our approach combines functional genetics, biochemistry, and small molecule screens, leveraging the zebrafish models of these high-risk human cancers we have recently developed.

Physician Video